LEADER 02378oam  2200649zu 450 
001 9910698683403321
005 20210807004703.0
035   $a(CKB)3450000000002106
035   $a(SSID)ssj0000621015
035   $a(PQKBManifestationID)11926328
035   $a(PQKBTitleCode)TC0000621015
035   $a(PQKBWorkID)10613426
035   $a(PQKB)10897833
035   $a(WaSeSS)Innodata00029870
035   $a(OCoLC)301351975
035   $a(EXLCZ)993450000000002106
100   $a20160829d2008      uy              
101 0 $aeng
135   $aur|||||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aHER2 testing to manage patients with breast cancer or other solid tumors
210 31$a[Place of publication not identified]$cU S Dept of Health and Human Services Agency for Healthcare Research and Quality$d2008
215   $a1 online resource
225 0 $aEvidence report/technology assessment   HER2 testing to manage patients with breast cancer or other solid tumors
300   $aBibliographic Level Mode of Issuance: Monograph
320   $aIncludes bibliographical references.
410  0$aEvidence report/technology assessment ;$vno. 172.
410  0$aAHRQ publication ;$vno. 09-E001.
606   $aBreast$xCancer
606   $aHER-2 gene$xCancer$xGene therapy
606   $aBreast
606   $aGenes, erbB-2$xgenetics
606   $aNeoplasms$xgenetics
606   $aAntibodies, Monoclonal$xtherapeutic use
606   $aAntineoplastic Agents$xtherapeutic use
606   $aGenetic Testing$xmethods
606   $aNeoplasms$xdrug therapy
608   $aReview.
615  0$aBreast$xCancer
615  0$aHER-2 gene$xCancer$xGene therapy
615  0$aBreast
615 12$aGenes, erbB-2$xgenetics.
615 12$aNeoplasms$xgenetics.
615 22$aAntibodies, Monoclonal$xtherapeutic use.
615 22$aAntineoplastic Agents$xtherapeutic use.
615 22$aGenetic Testing$xmethods.
615 22$aNeoplasms$xdrug therapy.
702   $aSeidenfeld$b Jerome
712 02$aBlue Cross and Blue Shield Association Technology Evaluation Center.
712 02$aUnited States Agency for Healthcare Research and Quality
801  0$bPQKB
906   $aBOOK
912   $a9910698683403321
996   $aHER2 testing to manage patients with breast cancer or other solid tumors$93177994
997   $aUNINA